Marquette Asset Management LLC Acquires New Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Marquette Asset Management LLC acquired a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 33,311 shares of the biotechnology company’s stock, valued at approximately $81,000.

A number of other hedge funds have also added to or reduced their stakes in ORMP. Dimensional Fund Advisors LP boosted its holdings in shares of Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares during the period. Renaissance Technologies LLC increased its stake in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the period. XTX Topco Ltd bought a new position in Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Murchinson Ltd. grew its holdings in Oramed Pharmaceuticals by 23.2% during the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after acquiring an additional 320,495 shares in the last quarter. Finally, BML Capital Management LLC increased its position in Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after purchasing an additional 837,153 shares during the period. 12.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP opened at $2.36 on Wednesday. Oramed Pharmaceuticals Inc. has a 12-month low of $2.00 and a 12-month high of $3.67. The stock’s fifty day simple moving average is $2.38 and its two-hundred day simple moving average is $2.41. The stock has a market capitalization of $95.14 million, a PE ratio of 21.45 and a beta of 1.67.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.